Complement C3 precursor biopolymer markers indicative of insulin resistance
View Patent ↗The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
1. An isolated biopolymer marker consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 or consisting of SEQ ID NO:3.
2. A method for determining in a patient sample the presence of a biopolymer marker consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 or consisting of SEQ ID NO:3 which is linked to insulin resistance comprising:
(a) obtaining a sample from a patient;
(b) conducting mass spectrometric analysis on said sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum profiles of said biopolymer marker consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 or consisting of SEQ ID NO:3 to mass spectrum profiles of peptides obtained and analyzed from said sample; and
(c) confirming the presence of said biopolymer marker consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 or consisting of SEQ ID NO:3 in said sample displaying a peak profile of said biopolymer marker
consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 or consisting of SEQ ID NO:3 in said mass spectrum profile;
whereby the presence of said biopolymer marker consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 or consisting of SEQ ID NO:3 is indicative of a link to insulin resistance.
3. The method of claim 2 , wherein said sample is an unfractionated body fluid or a tissue sample.
4. The method of claim 2 , wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.
5. The method of claim 2 , wherein said mass spectrometric analysis is selected from the group consisting of Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS, TOF-TOF, ESI-Q-TOF and ION-TRAP.
6. The method of claim 2 , wherein said patient is a human.
7. A kit for determining the presence of a biopolymer marker consisting of SEQ ID NO:1;
consisting of SEQ ID NO:2 or consisting of SEQ ID NO:3 comprising: (a) a peptide consisting of SEQ ID NO:1; consisting of SEQ ID NO:2 or consisting of SEQ ID NO:3 and (b) an antibody that binds to said peptide in a sample from a patient.
8. The kit of claim 7 , wherein said antibody is immobilized on a solid support.
9. The kit of claim 7 , wherein said antibody is labeled.